KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Depreciation & Amortization (CF) (2017 - 2025)

Historic Depreciation & Amortization (CF) for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to $139000.0.

  • Aquestive Therapeutics' Depreciation & Amortization (CF) fell 1257.86% to $139000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $565000.0, marking a year-over-year decrease of 4556.84%. This contributed to the annual value of $718000.0 for FY2024, which is 4661.71% down from last year.
  • Latest data reveals that Aquestive Therapeutics reported Depreciation & Amortization (CF) of $139000.0 as of Q3 2025, which was down 1257.86% from $140000.0 recorded in Q2 2025.
  • In the past 5 years, Aquestive Therapeutics' Depreciation & Amortization (CF) ranged from a high of $755000.0 in Q1 2021 and a low of $139000.0 during Q1 2025
  • Its 5-year average for Depreciation & Amortization (CF) is $412210.5, with a median of $325000.0 in 2023.
  • In the last 5 years, Aquestive Therapeutics' Depreciation & Amortization (CF) surged by 1763.22% in 2023 and then plummeted by 6852.25% in 2024.
  • Aquestive Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $731000.0 in 2021, then tumbled by 45.69% to $397000.0 in 2022, then grew by 17.63% to $467000.0 in 2023, then plummeted by 68.52% to $147000.0 in 2024, then decreased by 5.44% to $139000.0 in 2025.
  • Its Depreciation & Amortization (CF) was $139000.0 in Q3 2025, compared to $140000.0 in Q2 2025 and $139000.0 in Q1 2025.